新型蒽环类药物评估中生化与生物学方法的比较 - Suppr

Suppr

超能文献

Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs.

作者信息

Di Marco A, Zunino F, Casazza A M

出版信息

Antibiot Chemother (1971). 1978;23:12-20. doi: 10.1159/000401466.

DOI:10.1159/000401466

PMID:206196

Abstract

摘要

相似文献

Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs.新型蒽环类药物评估中生化与生物学方法的比较

Antibiot Chemother (1971). 1978;23:12-20. doi: 10.1159/000401466.

Methods of screening antitumor antibiotics.抗肿瘤抗生素的筛选方法。

Natl Cancer Inst Monogr. 1977 Mar(45):221-5.

Conformational preference for interaction of anthracycline antitumour antibiotics with chromatin.蒽环类抗肿瘤抗生素与染色质相互作用的构象偏好性。

Indian J Exp Biol. 1988 Jun;26(6):453-6.

[Comparative study of the antitumor action and toxicity of the antibiotic sibiromycin and its sulfur derivative].[抗生素西伯利亚霉素及其硫衍生物的抗肿瘤作用与毒性的比较研究]

Antibiotiki. 1974 Aug;19(8):714-7.

Experimental evaluation of anthracycline analogs.蒽环类类似物的实验评估

Cancer Treat Rep. 1979 May;63(5):835-44.

[Experimental study of the aitumor activity of the antibiotic sibiromycin].

Antibiotiki. 1970 Apr;15(4):300-4.

Bisantrene, biological and clinical effects.双胺苯吖啶的生物学及临床效应

Cancer Treat Rev. 1984 Dec;11(4):285-8. doi: 10.1016/0305-7372(84)90024-0.

[Combined use of rubomycin and olivomycin in treatment of murine lymphosarcoma].[柔红霉素与橄榄霉素联合用于治疗小鼠淋巴肉瘤]

Antibiotiki. 1972 Apr;17(4):325-9.

Stereochemical requirements in the antitumor anthracyclines.抗肿瘤蒽环类药物的立体化学要求。

J Antibiot (Tokyo). 1977 Sep;30(9):764-6. doi: 10.7164/antibiotics.30.764.

[The sensitivity of animal transplantable tumours to rubomycin].[动物可移植肿瘤对柔红霉素的敏感性]

Antibiotiki. 1967 Apr;12(4):315-9.

引用本文的文献

Synthesis, biological and biochemical properties of new anthracyclines modified in the aminosugar moiety.氨基糖部分修饰的新型蒽环类药物的合成、生物学及生物化学性质

Cancer Chemother Pharmacol. 1983;10(2):84-9. doi: 10.1007/BF00446215.

Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.4-去甲氧基柔红霉素（DMDR）治疗晚期肾细胞癌的II期试验。

Cancer Chemother Pharmacol. 1985;14(1):79-80. doi: 10.1007/BF00552731.

Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.蒽环类抗肿瘤药物。物理化学、分析及稳定性性质综述。

Pharm Weekbl Sci. 1986 Apr 25;8(2):109-33. doi: 10.1007/BF02086146.

Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.伊达比星（4-去甲氧基柔红霉素；IMI-30；NSC 256439）在晚期癌症患者中静脉内和口服给药后的药代动力学。

Br J Clin Pharmacol. 1987 Mar;23(3):303-10. doi: 10.1111/j.1365-2125.1987.tb03049.x.

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.

Invest New Drugs. 1986;4(3):275-8. doi: 10.1007/BF00179596.

Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).4-去甲氧基柔红霉素（DMDR）的临床药理学

Cancer Chemother Pharmacol. 1986;17(2):143-8. doi: 10.1007/BF00306743.

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.

Cancer Chemother Pharmacol. 1988;21(4):351-4. doi: 10.1007/BF00264204.

Phase II trial of idarubicin in patients with advanced lymphoma.伊达比星用于晚期淋巴瘤患者的II期试验。

Cancer Chemother Pharmacol. 1988;21(3):261-4. doi: 10.1007/BF00262782.

Anthracycline analogs: the past, present, and future.蒽环类类似物：过去、现在与未来。

Cancer Chemother Pharmacol. 1986;18(3):185-97. doi: 10.1007/BF00273384.

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.伊达比星。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。

Drugs. 1991 Oct;42(4):690-719. doi: 10.2165/00003495-199142040-00010.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验